4,7-dioxa-9-hydroxynonanamide | 105380-10-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4,7-dioxa-9-hydroxynonanamide
• 英文别名: 3-[2-(2-Hydroxyethoxy)ethoxy]propanamide
• CAS: 105380-10-7
• 化学式: C₇H₁₅NO₄
• 分子量: 177.2
• InChiKey: JFZNVJUCPRXWEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  81.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-[2-(2-羟基乙氧基)乙氧基]丙腈 在 双氧水 作用下， 以82%的产率得到4,7-dioxa-9-hydroxynonanamide
  参考文献：
  名称：

  Movsumzade, E. M.; Rasulbekova, T. I.; Kulieva, D. A., Journal of Organic Chemistry USSR (English Translation), 1985, vol. 21, # 11, p. 2132 - 2135

  摘要：

  DOI：

文献信息

• INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES
  申请人：MERCK SHARP & DOHME CORP.

  公开号：EP3922260A2

  公开（公告）日：2021-12-15

  The present invention provides compositions comprising insulin receptor partial agonists or insulin dimers in association with GLP-1 analogues (e.g., liraglutide) as well as methods for using the compositions for example, to treat or prevent diabetes or to decrease body weight.

  本发明提供了由胰岛素受体部分激动剂或胰岛素二聚体与GLP-1类似物（如利拉鲁肽）组成的组合物，以及使用这些组合物治疗或预防糖尿病或减轻体重的方法。
• Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
  申请人：Arvinas, Inc.

  公开号：US10723717B2

  公开（公告）日：2020-07-28

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，它们可用作快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；靶蛋白）的调节剂。特别是，本公开内容涉及双功能化合物，其一端含有与相应 E3 泛素连接酶结合的 Von Hippel-Lindau、cereblon、抑制细胞凋亡蛋白或小鼠双敏同源物 2 配体，另一端含有与靶蛋白 RAF 结合的分子，从而将靶蛋白置于泛素连接酶附近，以实现对靶蛋白的降解（和抑制）。本公开物具有与降解/抑制靶蛋白相关的广泛药理活性。本公开的化合物和组合物可以治疗或预防由于靶蛋白的聚集或积聚或靶蛋白的组成性激活而导致的疾病或失调。
• MOVSUMZADE, EH. M.;RASULBEKOVA, T. I.;KULIEVA, D. A.;ALIEV, G. R.;MOVSUMZ+, ZH. ORGAN. XIMII, 1985, 21, N 11, 2334-2337
  作者：MOVSUMZADE, EH. M.、RASULBEKOVA, T. I.、KULIEVA, D. A.、ALIEV, G. R.、MOVSUMZ+

  DOI：——

  日期：——
• INSULIN RECEPTOR PARTIAL AGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3221343B1

  公开（公告）日：2020-09-16